Kamada is an Israeli biopharmaceutical company specializing in plasma-based therapies. Its share price is driven by sales of its products, as well as revenue from distribution agreements with major pharmaceutical companies.
Kamada Ltd. is an Israeli biopharmaceutical company that produces specialized plasma protein-based medications and develops inhalation therapies. We classify it as a "Specialty Pharmaceuticals" company. The chart below shows the dynamics of this segment.
Kamada is an Israeli biopharmaceutical company that produces plasma protein-based drugs. As a leader in its niche, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Kamada's performance to assess the state of the sector.
The volatility of Kamada, an Israeli biopharmaceutical company specializing in plasma-derived drugs, reflects the state of this niche market. Change_co shows sensitivity to regulatory approvals. This metric is key to analyzing the specialty pharmaceuticals sector on System.GURU.Markets.
Kamada Ltd. is an Israeli biopharmaceutical company. This chart highlights the sector's high volatility. Comparing it to KMDA, which specializes in plasma-derived therapeutics, helps assess its unique risk profile in this niche.
Kamada is an Israeli biopharmaceutical company specializing in plasma-based therapies. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Kamada's stock performance.
For Kamada Ltd., an Israeli biopharmaceutical company, annual performance is a story about the production of plasma protein-based drugs. Its market capitalization over 12 months depends on sales volumes of its existing products and the success of clinical trials of new therapeutics, which ensures its stable market position.
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the production of plasma-based therapeutics. The chart shows how its niche expertise, diversified portfolio, and partnerships with major pharmaceutical companies contribute to its stable growth in the sector.
Kamada, an Israeli company producing plasma-derived medications, operates in the protective healthcare sector. Demand for its products is stable. Its share price (ADR) performance reflects not so much general cycles as its success in commercializing its products and establishing partnerships, making it a non-cyclical company.
Kamada, an Israeli biopharmaceutical company, has a market capitalization dependent on its product cycle. The monthly fluctuations on the chart reflect sales of its plasma-based drugs and revenue from distributing other companies' drugs, providing diversification.
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the production of plasma-derived drugs and the development of inhaled therapies. The dynamics of its sector, shown in the chart, serve as background. It is interesting to assess how its niche expertise and portfolio of commercialized products provide it with stability in the challenging pharmaceutical market.
Kamada is a pharmaceutical company with a stable plasma drug business. Its shares often act as a safe haven. The chart shows how the company's monthly fluctuations are isolated from overall market volatility and depend more on product news and financial results than on general panic or euphoria.
Kamada is an Israeli biopharmaceutical company specializing in plasma-based therapies. Its weekly stock price is driven by sales volumes and clinical trial successes for new therapeutics.
Kamada, like the entire specialty pharmaceutical sector, is responding to industry-wide events such as healthcare reforms and major M&A deals. The chart compares the company's performance with the overall state of its niche segment.
Kamada is an Israeli biopharmaceutical company. Its shares follow the rhythm of news about clinical trials and drug sales. The chart will show how its weekly performance is detached from general market trends, driven by its own unique events and the state of the Israeli market.
The Kamada Ltd. chart tells the story of niche plasma-based drugs. This Israeli biopharmaceutical company's market capitalization reflects both stable revenues from its existing products and investor confidence in its development of new drugs for rare diseases.
Kamada Ltd. is an Israeli biopharmaceutical company with a significant market share in plasma-based and inhalation therapies. Its market capitalization reflects its commercial product portfolio and its role as a contract manufacturer.
Kamada is a niche biopharmaceutical company. What's the size of the entire pharmaceutical industry? The chart below shows its total market capitalization. This is the gigantic arena in which this company has successfully carved out its niche, producing life-saving drugs based on plasma proteins.
The Kamada chart is a visualization of a niche business producing plasma-based drugs. The Israeli company's market capitalization reflects the stable demand for its products treating rare diseases, as well as the potential of its inhaled drug. This diagram demonstrates how specialization creates sustainable value.
The Israeli company Kamada's asset base is its plasma fractionation plant and specialized protein drug manufacturing facility. Its book value reflects the true value of this high-tech pharmaceutical production facility. The chart below shows how the value of these unique assets has changed.
Kamada Ltd. is an Israeli biopharmaceutical company whose strength lies in its own plasma fractionation and drug manufacturing facility. This high-tech facility is its key tangible asset. The chart shows the company's control over this specialized manufacturing infrastructure in its niche.
Kamada is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are capital-intensive. Kamada is a vertically integrated player. It owns the technology and manufacturing facilities to create plasma protein-based drugs.
Kamada's balance sheet is a plant in Israel that fractionates blood plasma and produces specialized protein products. The chart below shows the evolution of the value of this unique and complex production facility.
Kamada owns a unique plasma fractionation plant. The market pays a premium for their expertise in this complex and niche area of pharmaceuticals. The chart shows how this premium for their technological prowess has changed.
Kamada is an Israeli biopharmaceutical company producing plasma-based drugs. The chart shows how the market values its commercialized product portfolio and manufacturing capacity relative to their book value.
Kamada is an Israeli biopharmaceutical company that produces plasma-based drugs. Its valuation is a combination of stable revenue from its existing products and its R&D potential. Compared to the average, the market values both its manufacturing capabilities and its R&D pipeline, creating a mixed picture.
Kamada is an Israeli biopharmaceutical company specializing in plasma protein-based therapies. This chart illustrates its financial strategy. The company uses revenue from its commercialized products to fund the development of new drugs and expand its manufacturing capacity.
Kamada is an Israeli biopharmaceutical company specializing in plasma-derived drugs and providing contract manufacturing services. This dual business model influences its financial structure. This chart shows how the company's leverage reflects the balance between a stable manufacturing business and investments in proprietary product development.
Kamada is an Israeli biopharmaceutical company specializing in plasma-derived drugs. Producing these drugs requires significant investment in factories and adherence to strict standards. This chart shows its debt level, which helps assess how the company finances its capital-intensive operations and new product development.
Kamada is an Israeli biopharmaceutical company specializing in plasma protein-based drugs. This chart shows the leverage in the specialty pharmaceuticals sector. It helps understand how companies in this niche manage their manufacturing and research to create life-saving medicines.
Kamada Ltd. is an Israeli biopharmaceutical company producing plasma protein-based drugs. It has both established products and development pipelines. This graph of total market debt allows you to assess how the company balances stable revenue with investments in the future. Does it use debt to fund R&D or production expansion?
Kamada is an Israeli biopharmaceutical company specializing in plasma protein-based therapies, including a treatment for alpha-1 antitrypsin deficiency. This chart shows how investors value its niche business. The dynamics depend on sales volumes of existing products and progress in developing new ones.
Kamada is an Israeli biopharmaceutical company that produces specialized protein therapies derived from blood plasma. It also has a portfolio of distributed drugs. This chart shows the average valuation for the specialty pharmaceuticals sector, reflecting how investors value companies with unique technologies and hybrid business models.
Kamada is an Israeli biopharmaceutical company specializing in plasma-derived therapies. Its valuation depends on the commercial success of its products and the ability to expand their use. General market sentiment, reflected in this chart, has little impact on its business, which is driven by the specifics of the protein therapeutics market.
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the production of plasma-derived therapies. This chart reflects expectations for its niche products. The company's valuation depends on demand for its rare disease treatments and the success of its distribution agreements with major pharmaceutical partners.
%20P%2FE%20Kamada%20Ltd.&width=1500&height=450&colorIndex=35&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kamada-Ltd. "Chart of the company's future (projected) P/E Kamada Ltd.")
Kamada is an Israeli biopharmaceutical company that produces and distributes plasma protein-based drugs. This chart reflects the market's view of its niche business. Comparing its profit forecasts with the sector reveals how investors view its manufacturing capabilities and specialized product portfolio.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=36&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment "Future (projected) P/E graph of the market segment -")
Kamada is an Israeli biopharmaceutical company specializing in the production of plasma protein-based therapies. The company has both commercial products and development pipelines. While this graph of overall market sentiment influences sector valuation, Kamada prioritizes stable revenue from its current products and the success of its R&D.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole "Chart of the future (projected) P/E of the market as a whole")
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the production of plasma protein-based drugs. The company's profits depend on sales of its products and manufacturing contracts with other companies. This chart shows the financial results in a niche but important area of pharmaceuticals.
Kamada is an Israeli biopharmaceutical company specializing in plasma-derived and inhaled therapies for rare diseases. This specialty pharmaceutical profitability chart shows the robust demand for drugs for chronic and rare diseases, making the business model of these companies relatively stable.
Kamada is an Israeli biopharmaceutical company specializing in the production of plasma protein-based therapeutics. It manufactures both its own products and fulfills contract orders for major pharmaceutical companies. Its stable business exemplifies a niche yet important segment in the global pharmaceutical supply chain.
Kamada is an Israeli biopharmaceutical company specializing in plasma-based therapies. This chart shows expected sales of its existing products and success in developing new ones. Profits depend on plasma collection volumes and demand for its specialized medications.
%20profit%20of%20the%20company%20Kamada%20Ltd.&width=1500&height=450&colorIndex=41&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kamada-Ltd. "Graph of future (projected) profit of the company Kamada Ltd.")
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the production of plasma protein-based drugs. This chart reflects profitability forecasts for the pharmaceutical industry. It provides an opportunity to assess the stability of demand for the company's niche yet vital drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20&width=1500&height=450&colorIndex=42&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment "Graph of future (predicted) profits of companies in a market segment -")
This chart illustrates expectations for the Israeli biopharmaceutical company. Kamada's profit forecast depends on sales of its plasma-based products and revenue from the distribution of other companies' drugs. Stable plasma supplies and approval of new products determine its financial performance.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole "Chart of future (predicted) profits of the market as a whole")
Kamada is an Israeli biopharmaceutical company producing plasma-based drugs. This chart shows how investors value its revenue from existing products and the potential for new developments. The multiple reflects the stability of its niche business and pipeline expectations.
Kamada is a biopharmaceutical company that develops, manufactures, and markets protein-based therapeutics. Revenue is generated from both its own products and contract manufacturing for other companies. This chart shows the average valuation in the sector, allowing investors to understand how the market values Kamada's diversified revenue model and product portfolio.
Kamada is an Israeli biopharmaceutical company that produces specialized protein therapies, including those for the treatment of alpha-1 antitrypsin deficiency. Its revenue is generated through sales and licensing agreements. This graph, which displays Kamada's average revenue estimates, helps understand how the market values its niche products and manufacturing expertise.
Kamada is an Israeli biopharmaceutical company that produces specialized protein therapies derived from blood plasma. This chart shows how investors estimate its future revenue, which depends on demand for its existing products and the success of developing and commercializing new therapeutics.
%20P%2FS%20Kamada%20Ltd.&width=1500&height=450&colorIndex=47&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kamada-Ltd. "The graph of the company's future (projected) P/S Kamada Ltd.")
Kamada is an Israeli biopharmaceutical company specializing in the production of plasma protein-based therapies. This chart compares market expectations for its future revenue with those of other specialty pharmaceutical companies. The valuation reflects investor opinions on its product portfolio and contract manufacturing.
%20P%2FS%20market%20segment%20graph%20-%20&width=1500&height=450&colorIndex=48&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph "Future (projected) P/S market segment graph -")
Kamada is an Israeli biopharmaceutical company specializing in plasma protein-based therapies. Its revenue depends on sales of existing products and the success of new developments. Kamada's stability in its niche contributes to the overall health care sector, which is a vital part of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole "Chart of the future (projected) P/S of the market as a whole")
Kamada Ltd. is an Israeli biopharmaceutical company that manufactures and markets plasma protein-based therapies. This chart shows revenue from sales of its specialized products, such as drugs for the treatment of respiratory failure, as well as from distribution agreements.
Kamada Ltd. is an Israeli biopharmaceutical company that specializes in the production of plasma protein-based therapeutics and also provides contract manufacturing services to other companies. This chart shows overall sales in the pharmaceutical sector, reflecting the demand for specialized biologics and manufacturing capacity in this high-tech industry.
Kamada is an Israeli biopharmaceutical company specializing in the production of plasma protein-based drugs and the development of inhaled therapies. This overall economic activity profile impacts Kamada through global healthcare spending. Economic growth allows countries to spend more on specialized medications.
Kamada is an Israeli biopharmaceutical company that produces and distributes specialized plasma-derived protein therapies. This chart reflects analyst expectations for demand for its niche therapeutic products and the success of its distribution business.
%20sales%20of%20the%20company%20Kamada%20Ltd.&width=1500&height=450&colorIndex=53&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kamada-Ltd. "Schedule of future (projected) sales of the company Kamada Ltd.")
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the production of plasma protein-based drugs. This chart shows projected revenues for the entire pharmaceutical sector. While it provides a general overview, Kamada's primary focus is on demand for its specialized drugs and the success of its distribution business.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=54&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment "Schedule of future (projected) sales of companies in the market segment -")
Kamada is an Israeli biopharmaceutical company that produces plasma protein-based medications. Demand for its products is stable, as they are used to treat chronic and rare diseases. However, this growth rate, reflecting the global economic situation, impacts the budgets of healthcare systems, which are the primary customers of Kamada's products.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole "Schedule of future (predicted) sales of the market as a whole")
Kamada is an Israeli biopharmaceutical company specializing in plasma-based therapies. The chart shows the profitability of its commercialized products. This profit allows the company to fund research and development of new drugs, which is key to its long-term growth and success.
Kamada is an Israeli biopharmaceutical company specializing in the production of plasma-derived products. It has both in-house products and contract manufacturing. This chart shows how effectively Kamada manages its complex manufacturing and commercial operations compared to other specialized pharmaceutical companies.
Kamada is a biopharmaceutical company specializing in the production of plasma-derived therapeutics. The company's profitability depends on demand for its specialized therapeutic products and the efficiency of its manufacturing processes. This total market return chart highlights Kamada's performance in the niche healthcare sector, where demand is driven by medical needs rather than general economic cycles.
Kamada is an Israeli biopharmaceutical company specializing in the production of plasma protein-based drugs. This chart shows the team working in a niche sector. The team's growth reflects both sales of its own products and revenue from manufacturing services it provides to other companies.
This indicator highlights Kamada Ltd.'s unique niche. The Israeli company's pharmaceutical sector is focused on the production of plasma-derived drugs, such as alpha-1 antitrypsin, and the development of inhaled forms of these drugs. This team specializes in complex technology and serves patients with rare diseases.
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the production of plasma protein-based drugs. This is a complex and important segment of the pharmaceutical industry. This chart shows how niche drugmakers are contributing to global healthcare by creating jobs for highly skilled biologists and technologists.
Kamada Ltd. is an Israeli biopharmaceutical company specializing in plasma protein-based therapies. Demand for its products is driven by medical needs and is independent of economic cycles, as reflected in this chart. The company produces life-saving medications for the treatment of rare diseases.
Kamada is an Israeli pharmaceutical company producing plasma protein-based drugs. This chart reflects the specifics of biopharmaceutical manufacturing. The moderate capitalization per employee indicates that the company owns both intellectual property and sophisticated manufacturing facilities that require qualified personnel.
%20of%20the%20company%20Kamada%20Ltd.%20(KMDA)&width=1500&height=450&colorIndex=63&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kamada-Ltd.-KMDA "Chart of market capitalization per employee (in thousands of dollars) of the company Kamada Ltd. (KMDA)")
Kamada is an Israeli biopharmaceutical company specializing in plasma protein-based drugs. This metric reflects the value of its product portfolio and manufacturing expertise. The chart allows one to assess how the market perceives the company's potential in its niche compared to other pharmaceutical manufacturers.
%20by%20market%20segment%20-%20&width=1500&height=450&colorIndex=64&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment "Market capitalization per employee (in thousands of dollars) by market segment -")
Kamada Ltd. is an Israeli biopharmaceutical company producing plasma protein-based drugs. This chart shows the market valuation of its niche manufacturing process. The high valuation per employee may be due to the complexity of its technology and the availability of long-term contracts for the supply of its specialized products.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market "Market capitalization per employee (in thousands of dollars) for the overall market")
Kamada is an Israeli biopharmaceutical company. They produce plasma protein-based drugs (for example, for the treatment of rabies) and distribute other medications in Israel. This chart shows the profitability of this hybrid model: how profitable their own production is and how efficient their distribution is.
%20Chart%20Kamada%20Ltd.%20(KMDA)&width=1500&height=450&colorIndex=66&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kamada-Ltd.-KMDA "Company Profit Per Employee (in thousands of dollars) Chart Kamada Ltd. (KMDA)")
Kamada is an Israeli biopharmaceutical company. It specializes in plasma-derived drugs and also has a profitable distribution business in Israel. This chart shows how effectively the company combines in-house manufacturing and distribution. It serves as a benchmark for assessing the profitability of this hybrid model compared to other niche pharmaceutical companies.
%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=67&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment "Chart of profit per employee (in thousands of dollars) in the market segment -")
Kamada (KMDA) is an Israeli biopharmaceutical company specializing in plasma-derived drugs (for example, for the treatment of alpha-1 antitrypsin deficiency). This is a niche product. This chart shows the profitability of their product portfolio. Manufacturing such drugs is complex and expensive, but their prices are also high. This metric reflects their ability to effectively manage this process.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Kamada is an Israeli biopharmaceutical company specializing in plasma protein-based drugs. This chart shows performance in the niche pharmaceutical industry. Revenue per employee is generated through sales of its own products and contract manufacturing for other companies.
&width=1500&height=450&colorIndex=69&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kamada-Ltd.-KMDA "Sales chart per company employee Kamada Ltd. (KMDA)")
Kamada Ltd. is an Israeli biopharmaceutical company specializing in plasma-derived products. This chart shows the average revenue per employee in the segment. It allows one to assess how productive their specialized manufacturing and R&D are compared to other companies operating in the blood products sector.
Kamada is an Israeli biopharmaceutical company. They specialize in plasma-derived drugs and also act as a contract manufacturer. This chart shows how their R&D team and manufacturing facility generate revenue from sales of these niche, complex-to-manufacture drugs.
Kamada is an Israeli biopharmaceutical company specializing in plasma-derived drugs. The bearish sentiment seen in this chart may be related to intense competition in the plasma sector (CSL, Takeda) or risks associated with its distribution agreements, which may not be renewed.
&width=1500&height=450&colorIndex=72&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kamada-Ltd.-KMDA "Short Shares Chart for the Company Kamada Ltd. (KMDA)")
Kamada Ltd. is an Israeli biopharmaceutical company specializing in plasma-derived drugs and rabies treatments. This chart shows the overall sentiment in the sector, reflecting investor concerns about competition in the plasma-derived drug market and the risks associated with niche pharmaceutical markets.
Kamada (KMDA) is an Israeli biopharmaceutical company producing plasma-based drugs. It has a stable business, but it's also a small company in a volatile market. This chart shows the overall level of market pessimism. When it's high, even profitable but small companies like KMDA can be caught in the general sell-off.
Kamada is an Israeli biopharmaceutical company specializing in plasma-derived drugs (for example, for the treatment of rabies). This chart measures how investors view this niche but stable market. It shows when the stock is overbought on growth expectations or oversold on competitive fears.
&width=1500&height=450&colorIndex=75&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kamada-Ltd.-KMDA "RSI 14 indicator chart for the company's stock Kamada Ltd. (KMDA)")
Kamada is an Israeli biopharmaceutical company. They specialize in plasma-derived therapies (for example, for the treatment of alpha-1 antitrypsin deficiency) and are also a CDMO. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Kamada compares to that.
Kamada (KMDA), a pharmaceutical company. This chart reflects the mood in the sector. During periods of euphoria, investors are willing to fund R&D. In times of panic, they look for companies with existing sales. KMDA, with both, may be more stable than pure biotechs.
Kamada (KMDA) is an Israeli biopharmaceutical company specializing in plasma protein-based therapies. This chart shows the average 12-month analyst forecast. It reflects their expectations for sales of key products (such as rabies) and revenue from distribution agreements, which are a crucial part of the company's business model.
&width=1500&height=450&colorIndex=78&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KMDA-Kamada-Ltd. "A chart showing analyst consensus forecasts for the expected stock price. KMDA (Kamada Ltd.)")
Kamada is an Israeli pharmaceutical company specializing in the production of plasma-derived medications (such as AAT for the treatment of emphysema) and the distribution of niche drugs. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in this niche yet stable business model.
&width=1500&height=450&colorIndex=79&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KMDA-Kamada-Ltd. "A chart showing the difference between the consensus forecast and the actual stock price. KMDA (Kamada Ltd.)")
Kamada is an Israeli biopharmaceutical company specializing in plasma-derived drugs (for example, for the treatment of alpha-1 antitrypsin deficiency). This chart shows analysts' overall expectations for the specialty pharmaceuticals sector. It reflects whether experts believe there will be stable demand for niche protein drugs.
Kamada is an Israeli biopharmaceutical company specializing in plasma-derived drugs (for example, for the treatment of rabies). This is a niche, "defensive" sector. This chart shows general market sentiment. For Kamada, whose demand is stable, these general expectations (market noise) are less important than their contracts with the Ministry of Health and R&D. (341)
Kamada is an Israeli biopharmaceutical company with a hybrid model. They have two segments: Proprietary (developing and selling plasma-based therapies) and Distribution (serving as a distributor for pharma giants in Israel). This chart is a summary indicator of their model. It likely balances the stability of distribution with the growth of their high-margin, proprietary drugs.
Kamada (KMDA) is an Israeli biopharmaceutical company specializing in the production of life-saving plasma-derived therapies (e.g., for the treatment of AAT deficiency) and also operates as a distributor. This summary metric evaluates R&D. The graph shows the segment average. This benchmark provides insight into how Kamada's niche (plasma) and hybrid (R&D + distribution) model differentiates it from the average pharma company.
Kamada is a biopharmaceutical company specializing in plasma-derived therapies. It is a leader in the treatment of alpha-1 antitrypsin deficiency. This chart, reflecting the market average, is a backdrop. It helps assess how this niche but stable business compares to overall macroeconomic trends in healthcare.
